[HTML][HTML] The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy
Z Mitri, T Constantine, R O'Regan - Chemotherapy research and …, 2012 - hindawi.com
Human epidermal growth factor receptor 2 (HER2) is overexpressed in around 20–30% of
breast cancer tumors. It is associated with a more aggressive disease, higher recurrence rate, …
breast cancer tumors. It is associated with a more aggressive disease, higher recurrence rate, …
[HTML][HTML] Implementing a comprehensive translational oncology platform: from molecular testing to actionability
ZI Mitri, S Parmar, B Johnson, A Kolodzie… - Journal of translational …, 2018 - Springer
Background In order to establish the workflows required to implement a real-time process
involving multi-omic analysis of patient samples to support precision-guided therapeutic …
involving multi-omic analysis of patient samples to support precision-guided therapeutic …
[HTML][HTML] Delivering exercise medicine to cancer survivors: has COVID-19 shifted the landscape for how and who can be reached with supervised group exercise?
Purpose Due to stay-at-home orders during COVID-19, we transitioned supervised, group, in-person
resistance training interventions in two clinical trials in cancer survivors to live, …
resistance training interventions in two clinical trials in cancer survivors to live, …
[HTML][HTML] Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors
Metastatic progression defines the final stages of tumor evolution and underlies the majority
of cancer-related deaths. The heterogeneity in disseminated tumor cell populations capable …
of cancer-related deaths. The heterogeneity in disseminated tumor cell populations capable …
Everolimus plus exemestane treatment in patients with metastatic hormone receptor‐positive breast cancer previously treated with CDK4/6 inhibitor therapy
…, AJ Kaempf, MM Saraceni, MA Savin, ZI Mitri - The …, 2021 - academic.oup.com
Background The combination of everolimus (EVE) and exemestane (EXE) is approved for
the treatment of patients with metastatic hormone receptor‐positive breast cancer (mHRBC) …
the treatment of patients with metastatic hormone receptor‐positive breast cancer (mHRBC) …
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast …
Z Mitri, C Karakas, C Wei, B Briones, H Simmons… - Investigational new …, 2015 - Springer
Purpose, Low molecular weight cyclin E (LMW-E) isoforms, overexpressed in a majority (~70
%) of triple-negative breast cancers (TNBC), were found in preclinical models to mediate …
%) of triple-negative breast cancers (TNBC), were found in preclinical models to mediate …
CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real‐world practice
…, JL Choung, A Palumbo, Z Mitri… - European journal of …, 2021 - Wiley Online Library
Purpose Cyclin‐dependent kinase (CDK) 4/6 inhibitors are integral treatment for advanced
hormone receptor positive breast cancer; however, venous thromboembolic events (VTE) …
hormone receptor positive breast cancer; however, venous thromboembolic events (VTE) …
[HTML][HTML] Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics
Molecular heterogeneity in metastatic breast cancer presents multiple clinical challenges in
accurately characterizing and treating the disease. Current diagnostic approaches offer …
accurately characterizing and treating the disease. Current diagnostic approaches offer …
[HTML][HTML] Impact of TP53 mutations in triple negative breast cancer
ZI Mitri, N Abuhadra, SM Goodyear, EA Hobbs… - npj Precision …, 2022 - nature.com
Identifying triple negative breast cancer (TNBC) patients expected to have poor outcomes
provides an opportunity to enhance clinical management. We applied an Evolutionary Action …
provides an opportunity to enhance clinical management. We applied an Evolutionary Action …
[PDF][PDF] An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer
…, BL Kong, M Labrie, J Lee, P Leyshock, S Mitri… - Cell Reports …, 2022 - cell.com
Mechanisms of therapeutic resistance and vulnerability evolve in metastatic cancers as tumor
cells and extrinsic microenvironmental influences change during treatment. To support the …
cells and extrinsic microenvironmental influences change during treatment. To support the …